Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol for sedation in gastrointestinal endoscopy
ChiCTR2100045603Phase 4Recruiting
- Sponsor
- Yantai Yeda Hospital
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in gastrointestinal conditions (4 arms), sponsored by Yantai Yeda Hospital. Primary endpoint: Modified alertness and sedation score. Started Mar 2021; status: recruiting.
02
Drugs
remimazolam
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR2100045603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045603.